Vimarsana
Biggest News Aggregation in the World

Page 9 - Mathilde Bohin News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mathilde Bohin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mathilde Bohin Today - Breaking & Trending Today

ERYTECH Requested a Pre-BLA Meeting with the FDA to Discuss Path to Approval in ALL - Vimarsana News

ERYTECH Requested a Pre-BLA Meeting with the FDA to Discuss Path to Approval in ALL

Press release content from Globe Newswire. The AP news staff was not involved in its creation. ERYTECH Requested a Pre-BLA Meeting with the FDA to Discuss Path to Approval in ALL Erytech Pharma S.A.April 20, 2021 GMT ERYTECH Requested a Pre-BLA Meeting with the FDA to Discuss Path to Approval in ALL ERYTECH invited by FDA to request a pre-BLA meeting First step in the marketing approval process with the FDA for eryaspase for the treatment of hypersensitive ALL patients based on the positive results of the NOPHO-sponsored Phase 2 clinical trial Lyon (France) and Cambridge, MA (U.S.), April 2...

Source: apnews.com
ERYTECH Announces Completion of First Cohort in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer - Vimarsana News

ERYTECH Announces Completion of First Cohort in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer

. The rESPECT IST (NCT04292743) is a single arm, dose escalating Phase 1 clinical trial to evaluate the safety of eryaspase in combination with modified FOLFIRINOX. The trial is conducted by Dr Marcus Noel, Associate Professor of Medicine at Georgetown University, Washington DC, USA, and will enroll approximately 18 patients who have received no prior chemotherapy for the treatment of locally advanced or metastatic pancreatic cancer. FOLFIRINOX is one of the most commonly utilized first-line chemotherapy regimens for the treatment of pancreatic cancer, despite its toxicity. The trial was laun...

ERYTECH Announces Completion of First Cohort in a Phase 1 Investigator Sponsored Trial of ... - Vimarsana News

ERYTECH Announces Completion of First Cohort in a Phase 1 Investigator Sponsored Trial of ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. ERYTECH Announces Completion of First Cohort in a Phase 1 Investigator Sponsored Trial of ... Erytech Pharma S.A.April 19, 2021 GMT ERYTECH Announces Completion of First Cohort in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer No dose-limiting toxicity reported in the first dose cohort Encouraging clinical activity observed in first patients Trial will be escalated to the next dose Lyon (France) and Cambridge, MA (U.S.), April 19, 2021 – ERYTECH Pharma (Nasd...

Source: apnews.com
Implanet Receives TGA Clearance for the MADISONTM Total Knee Prosthesis in Australia - Vimarsana News

Implanet Receives TGA Clearance for the MADISONTM Total Knee Prosthesis in Australia

Recognition of the range of implants developed by Implanet to address a high potential marketNew milestone in the commercialization of the MADISONTM prosthesis in partnership with KICoBORDEAUX, France & BOSTON--(BUSINESS WIRE)--Regulatory News:IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME equity savings plans) (Paris:ALIMP), a medical technology company

Implanet Confirms Offer to Acquire a Majority Stake in Orthopaedic & Spine Development - Vimarsana News

Implanet Confirms Offer to Acquire a Majority Stake in Orthopaedic & Spine Development

Implanet Confirms Offer to Acquire a Majority Stake in Orthopaedic & Spine Development Orthopaedic Spine Development ("OSD") is a manufacturer of implants for spine surgery Acquisition of a majority interest will lead to the creation of a new benchmark player in orthopedic surgery in France and allow the Group to rapidly achieve significant revenue growth. Regulatory News: IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME equity savings plans), a medical technology company specializing in vertebral and knee-surgery implants, today announces that it has obtained founding sha...